Innovative Assay Kits for Next-Generation Drug HTS

• Direct contact technical support
• Find products for your research

Small-molecule drugs are low-molecular-weight chemical entities, typically less than 900 Da, designed to modulate specific biological targets such as enzymes, receptors, and ion channels. After target validation, the discovery of lead compounds relies on extensive screening approaches, commonly divided into cell-based assay and cell-free assay methodologies.

To accelerate these workflows, Vazyme offers a comprehensive process and multi‑dimensional solution spanning early-stage R&D through process development, helping teams overcome key bottlenecks. The platform leverages cutting-edge technology and customized services to integrate smoothly into existing discovery pipelines.

Why choose Vazyme’s assay kits

• Stable performance for scale: Batch-to-batch CV < 15%, making the kits well-suited for large-scale library screening.
• Broad dynamic range: Wider detection range with an improved detection window and linear range for robust pharmacology readouts.
• Time and labor savings: No-wash kits that save over 80% of process steps and reduce error sources during screening.
• Practical day-to-day handling: Maintains ~85% activity for 7 days at room temperature, minimizing freeze–thaw cycles.
• See here how it works.

Vazyme’s HTS portfolio includes cell-based assay kits covering cell viability and reporter assay formats as well as TR‑FRET kits designed for no-wash detection (e.g., IgG, cAMP, cytokines) with options for customization. Each product is supported by rigorous quality control, strong technical support and clear documentation to streamline adoption.

Whether you operate in research, big pharma, biotech or CRO environments, Vazyme helps you stay ahead with reliable, scalable and cost‑effective HTS solutions.